000079071 001__ 79071
000079071 005__ 20191126134629.0
000079071 0247_ $$2doi$$a10.1016/j.ejpb.2018.04.016
000079071 0248_ $$2sideral$$a106410
000079071 037__ $$aART-2018-106410
000079071 041__ $$aeng
000079071 100__ $$aKoloczek, P.
000079071 245__ $$aPolymeric micelle-mediated delivery of half-sandwich ruthenium(II) complexes with phosphanes derived from fluoroloquinolones for lung adenocarcinoma treatment
000079071 260__ $$c2018
000079071 5060_ $$aAccess copy available to the general public$$fUnrestricted
000079071 5203_ $$aNovel half-sandwich ruthenium(II) complexes with aminomethyl(diphenyl)phosphine derived from fluoroloquinolones (RuPCp, RuPSf, RuPLm, RuPNr) were being investigated as alternatives to well-established metal-based chemotherapeutics. All compounds were characterized by elemental analysis, selected spectroscopic methods (i.e., absorption and fluorescence spectroscopies, ESI-MS, NMR, circular dichroizm), X-ray diffractometry, ICP-MS, and electrochemical techniques. To overcome low solubility, serious side effects connected with systemic cytotoxicity of ruthenium complexes, and acquiring the resistance of cancer cells, polymeric nanoformulations based on Pluronic P-123 micelles loaded with selected Ru(II) complexes were prepared and characterized. Resulting micelles (RuPCp_M, RuPNr_M) enabled efficient drug accumulation inside human lung adenocarcinoma (A549 tumor cell line), proved by confocal microscopy and ICP-MS analysis, allowing cytotoxic action. Studied complexes exhibited promising cytotoxicity in vitro with IC50 values significantly lower than the reference drug – cisplatin. The fluorescence spectroscopic data (CT-DNA titration, in vitro cell staining) together with analysis of DNA fragmentation (pBR322 plasmid, comet assay) provided clear evidence for the interaction with DNA inducing apoptotic cell death.
000079071 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/CIBER-BBN
000079071 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000079071 590__ $$a4.708$$b2018
000079071 591__ $$aPHARMACOLOGY & PHARMACY$$b28 / 266 = 0.105$$c2018$$dQ1$$eT1
000079071 592__ $$a1.326$$b2018
000079071 593__ $$aBiotechnology$$c2018$$dQ1
000079071 593__ $$aPharmaceutical Science$$c2018$$dQ1
000079071 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000079071 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000079071 700__ $$aSkórska-Stania, A.
000079071 700__ $$aCierniak, A.
000079071 700__ $$0(orcid)0000-0002-6873-5244$$aSebastian, V.$$uUniversidad de Zaragoza
000079071 700__ $$aKomarnicka, U.K.
000079071 700__ $$aPlotek, M.
000079071 700__ $$aKyziol, A.
000079071 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000079071 773__ $$g128 (2018), 69-81$$pEur. j. pharm. biopharm.$$tEuropean Journal of Pharmaceutics and Biopharmaceutics$$x0939-6411
000079071 8564_ $$s2092332$$uhttps://zaguan.unizar.es/record/79071/files/texto_completo.pdf$$yPostprint
000079071 8564_ $$s53425$$uhttps://zaguan.unizar.es/record/79071/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000079071 909CO $$ooai:zaguan.unizar.es:79071$$particulos$$pdriver
000079071 951__ $$a2019-11-26-13:40:11
000079071 980__ $$aARTICLE